BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Authors » Larry Haimovitch

Larry Haimovitch

Articles

ARTICLES

J.P. Morgan Healthcare 2012 Conference: Private companies make their pitches to receptive audience

Jan. 18, 2012
By Larry Haimovitch

2011 Canaccord Genuity Conference: Depsite struggling economy, aesthetics companies upbeat

Dec. 13, 2011
By Larry Haimovitch

Smaller companies pique the interest of Wells Fargo attendees

Aug. 1, 2011
By Larry Haimovitch

Smaller companies pique the interest of conference attendees

July 5, 2011
By Larry Haimovitch

For VC firms, FDA regulations at front of discussion topics

June 22, 2011
By Larry Haimovitch
SAN FRANCISCO — The 19th annual Medical Device Conference, sponsored by the influential law firm of Wilson Sonsini Goodrich & Rosati (WSG&R; Palo Alto, California) was held here this week at a new venue, the historic Palace Hotel in downtown San Francisco. (Medical Device Daily)
Read More

WSG&R presenters are hot and cold on med-tech funding

June 20, 2011
By Larry Haimovitch
SAN FRANCISCO — The 19th annual Medical Device Conference sponsored by the influential law firm of Wilson Sonsini Goodrich & Rosati (WSG&R; Palo Alto, California) was held here this week at a new venue, the historic Sheraton Palace in downtown San Francisco. (Medical Device Daily)
Read More

Atrial fibrillation still at the heart of annual HRS meeting

June 1, 2011
By Larry Haimovitch

CardioFocus demonstrates notable progress for AF

May 12, 2011
By Larry Haimovitch
SAN FRANCISCO — As discussed in Tuesday's issue of Medical Device Daily, there has been considerable progress in treating atrial fibrillation (AF) with catheter-based technologies in recent years. However, the rate of success, estimated at 57% for a single procedure, is far from satisfactory. Thus, the quest for better methods to perform AF catheter ablation continues at a strong pace. One company, which is demonstrating impressive progress, is privately-owned, venture capital-backed CardioFocus (Marlborough, Massachusetts). (Medical Device Daily)
Read More

AF still at the heart of annual HRS meeting

May 10, 2011
By Larry Haimovitch
SAN FRANCISCO — As has been the case in recent years, the 32nd annual scientific sessions of the Heart Rhythm Society (HRS; Washington) sponsored an AF Summit, focusing attention on atrial fibrillation (AF) with a full day of presentations. (Medical Device Daily)
Read More

Presenters tout big advances with lasers in cataract surgery

March 29, 2011
By Larry Haimovitch
View All Articles by Larry Haimovitch

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing